首页> 外文期刊>Korean Circulation Journal >Clinical and Echocardiographic Changes after Short-Term Denopamine (Cardopamin?) Therapy in Patients with Chronic Congestive Heart Failure
【24h】

Clinical and Echocardiographic Changes after Short-Term Denopamine (Cardopamin?) Therapy in Patients with Chronic Congestive Heart Failure

机译:慢性充血性心力衰竭患者短期应用多巴酚丁胺(卡多巴明)治疗后的临床和超声心动图变化

获取原文
           

摘要

Background Inotropic agents have been shown to improve cardiac function in patients with congestive heart failure. The purpose of the present study is to evaluate the short-term efficacy and safety of denopamine(Cardopamin?), and orally available β-stimulant, in patients with chronic congestive heart failure. Subjects and Methods Twenty-four patients(54.1±10.9 years, male:female=1.4:1) with chronic congestive heart failure whose functional classes were equal or greater than New York Heart Association(NYHA) Class II were enrolled in this study after informed consents were obtained. Upon completion of baseline evaluation, denopamine(Cardopamin?) was administered orally, startion with 15 mg per day and increased to 30 mg per day according to the clinical response of each patient. Blood pressure, heart rate, electrocardiographic(EKG) findings, AST, BUN, and creatinine were also followed up at 4 weeks' interval. The clinical effects and side effects at 4 weeks' interbal and echocardiographic examination at baseline and 8 weeks after trentment were evaluated. Results Mean dosage of denopamine(Cardopamin?) was 22.9±5.3mg per day. The clinical symptoms of 18(75%) of 24 patients were improved. The echocardiographic follow-up revealed a significant decrease in left vetricular(LV) end-Systolic dimemsion(fron 4.8±0.2mm to 4.5±0.1mm. p Conclusion Above results suggest that short-term therapy of denopamine(Cardopamin?) may improve clinical symptom with no side effect in patients with chronic congestive heart failure, but the long-term efficacy remains to be determined with a randomized long-term follow up study.
机译:背景已经显示出正性肌力药可以改善充血性心力衰竭患者的心功能。本研究的目的是评估在慢性充血性心力衰竭患者中使用多巴酚丁胺(Cardopamin?)和口服β-兴奋剂的短期疗效和安全性。研究对象和方法24例(54.1±10.9岁,男:女= 1.4:1)慢性充血性心力衰竭患者,其功能级别等于或大于纽约心脏协会(NYHA)II级,入选本研究获得同意。在完成基线评估后,根据每位患者的临床反应,以每天15 mg的起始剂量口服口服鸦片剂(Cardopamin?),并增加至每天30 mg。每隔4周对患者的血压,心率,心电图(EKG),AST,BUN和肌酐进行随访。评估基线和ment痛后8周进行耳蜗和超声心动图检查4周的临床效果和副作用。结果每天服用2mg±2mg的多巴酚丁胺(Cardopamin?)的平均剂量。 24例患者中有18例(75%)的临床症状得到改善。超声心动图随访发现左室舒张末期左室收缩压明显降低(从4.8±0.2mm到4.5±0.1mm。p)结论以上结果表明,短期使用多巴酚丁胺(Cardopamin?)可能改善临床慢性充血性心力衰竭患者无任何症状,但是否需要长期随机随访研究确定其长期疗效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号